资料发布时间:2018-10-30 14:50:00 最后更新时间: 2021-06-09 15:17:08
【药品简介】 恩杂鲁胺(Enzalutamide)是一种雄激素受体抑制剂,它作用于雄激素受体信号通路的步骤不同。研究表明,苯丙胺能抑制雄激素受体与雄激素受体的结合,抑制雄激素受体的核易位和与DNA的相互作用。
【适应症状】 恩杂鲁胺,恩杂鲁胺适用于抗肿瘤药多西他赛治疗后的前列腺癌患者。
【 药品别名 】 恩杂鲁胺 Enzalutamide
印度恩杂鲁胺(恩杂鲁胺 Enzalutamide)价格,正品图片,治疗前列腺癌药物, 购买恩杂鲁胺请到印度药房官方网站进行购买 【印度药房大全目录】
【 市场参考价格 】 ¥4000.00~5136.00
播放/暂停
生物活性
产品描述 |
Enzalutamide (MDV 3100) is a non-steroidal androgen receptor (AR) antagonist (IC50: 36 nM in LNCaP prostate cells). |
靶点活性 |
Androgen Receptor,36nM |
实验溶液 |
2% DMSO+30% PEG300: 5 mg/mL |
体外活性 |
Enzalutamide (MDV 3100) bound AR in castration-resistant LNCaP/AR human prostate cancer cells with 5-8 fold greater affinity than bicalutamide. MDV3100 antagonized induction of PSA and TMPRSS2 by the synthetic androgen R1881 in parental LNCaP cells. In the human prostate cancer cell line VCaP which has endogenous AR gene amplification, MDV3100 suppressed growth and induced apoptosis [1]. |
体内活性 |
Enzalutamide (10 mg/kg) induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts [1]. After intravenous injection (Enzalutamide, 0.5-5 mg/kg), systemic clearance, volumes of distribution at steady state (Vss), and half-life (T½) remained unaltered as a function of dose, with values in the ranges of 80.4-86.3 mL/h/kg, 1020-1250 mL/kg, and 9.13-10.6 h, respectively. Following oral administration, absolute oral bioavailability was 89.7 % and not dose-dependent [2]. |
激酶实验 |
AR reporter assay: Enzalutamide is evaluated by an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells are engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells are also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer. The antagonistic activity of Enzalutamide is tested in the presence of 100 pM of R1881. Engineered LNCaP cells are maintained in Iscove's medium containing 10% fetal bovine serum (FBS). Two days prior to Enzalutamide treatment, the cells are grown in Iscove's medium containing 10% charcoal-stripped FBS (CS-FBS) to deprive of androgens. The cells are split and grown in Iscove's medium containing 10% CS-FBS with 100 pM of R1881 and increasing concentrations of Enzalutamide. After two days of incubation, reporter activities are assayed. |
细胞实验 |
For in vitro experiments, LNCaP or LNCaP/AR cells (10^4 cells/well) were androgen-starved by growth in media containing 5-10% charcoal-stripped serum for 3-5 days. Then the cells were challenged with various concentrations of R1881, bicalutamide, RD162 or MDV3100 in media containing 5-10% charcoal-stripped serum [1]. 细胞系: LNCaP or LNCaP/AR cells |
动物实验 |
In vivo tumorigenicity experiments were done by subcutaneous injection of 10^6 cells (100 uL in 50% Matrigel and 50% growth media) into the flanks of castrated male SCID mice. Daily gavage treatment (using a formulation of 1% carboxymethyl cellulose, 0.1% Tween-80, 5% DMSO) was initiated when tumor size reached ~100 mm3. Tumor size was measured weekly in three dimensions (l x w x d) with calipers. For in vivo luciferase imaging, d-luciferin substrate (100 μL, 15 mg/mL) was injected intraperitoneally. After 5 minutes, mice were anesthetized using isofluorane and imaged using a cooled charged-coupled device IVIS camera. Data were analyzed using Living Image 2.30 software [1]. 动物模型:Castration-resistant LNCaP/HR xenografts in SCID mice |
化学信息
分子量 |
464.44 |
分子式 |
C21H16F4N4O2S |
CAS |
915087-33-1 |
溶解度 |
DMSO: 85 mg/mL (183 mM) Ethanol: <1 mg/mL ( < 1 mg/ml refers to the product slightly soluble or insoluble ) |
储存条件 |
store at -80°C |
备注 |
For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
配制溶液
1 mg | 5 mg | 10 mg | |
1 mM | 2.153 ml | 10.766 ml | 21.531 ml |
5 mM | 0.431 ml | 2.153 ml | 4.306 ml |
10 mM | 0.215 ml | 1.077 ml | 2.153 ml |
50 mM | 0.043 ml | 0.215 ml | 0.431 ml |
前列腺癌是一种很严重的疾病,如果不小心患上这种疾病一定要尽快治疗,其中恩杂鲁胺就是一款治疗前列腺癌的药物,下面大家就一起......
前列腺癌患者应注意本病的治疗,因为如果病情继续恶化,不仅会影响身体其他组织的健康,还可能危及生命,临床治疗这种疾病的药物......
恩杂鲁胺是由日本安斯泰来制药研发的前列腺靶向药物,被批准用于治疗转移性去势抵抗前列腺癌和非转移性去势抵抗前列腺癌。 作为......
恩杂鲁胺主要是雄激素受体抑制剂,可抑制雄性激素受体信号传递的多重步骤,包括抑制雄性激素与受体的结合、抑制受体的核转位以及......
前列腺癌是欧美等西方发达国家男性中发病率最高、病死率第二高的恶性肿瘤。在我国,前列腺癌的发病率近年来也呈显著上升趋势。 ......
推荐剂量,每日一次,每次1000mg(4*250mg片)...
前列腺癌骨转移能治,但是治不好...
前列腺癌临床上可分为局限性前列腺癌,局部晚期前列腺癌和晚期前列腺癌。...
对于早期前列腺癌患者,可采用根治性的治疗方法,能够治愈早期前列腺癌的方法。...
Pharmacy Catalogue
【代购】【有实体店】【在线客服懂中文】
代购+直邮,印度抗癌药跨境医药电商直邮服务,让肿瘤患者能够有更好的选择,平台提供印度就医,印度易瑞沙,吉三代,吉二代,索......
【禁止中国访问 】【印度连锁】【品牌实力】
MedPlus是印度第二大药房连锁店。它经营1555家商店,其中1317家为公司所有,159家为特许经营公司,43家为医......
【药品种类丰富 】【渠道正规】【价格较高】
Wellness Forever是一家生活方式零售药房连锁店,致力于为印度本土客户提供全面的健康服务。目前总收入约为62......
【visa/万事达】 【全球可邮 】【纯线上销售】【可开处方】
Netmeds.com致力于开发印度本土市场,已成为印度领先的在线药店。Netmeds.com通过其全天候在线门户和移动......